AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q02809

UPID:

PLOD1_HUMAN

Alternative names:

Lysyl hydroxylase 1

Alternative UPACC:

Q02809; B4DR87; Q96AV9; Q9H132

Background:

Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1, also known as Lysyl hydroxylase 1, plays a crucial role in collagen synthesis. It catalyzes the hydroxylation of lysine residues in collagen alpha chains, a process essential for the normal assembly and cross-linking of collagen fibrils. This enzymatic activity contributes to the formation of hydroxylysine residues, which are critical for the stability of intermolecular collagen cross-links.

Therapeutic significance:

The protein's involvement in Ehlers-Danlos syndrome, kyphoscoliotic type, 1, underscores its therapeutic significance. This condition, characterized by severe muscle hypotonia, joint laxity, and scleral fragility, highlights the protein's potential as a target for therapeutic intervention. Understanding the role of Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 could open doors to potential therapeutic strategies for connective tissue disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.